Sarepta discontinued SRP-5051 development due to safety concerns, despite promising Phase 2 results in dystrophin expression and exon skipping. Persistent hypomagnesemia and declining kidney function ...
The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...
Discover the iOS 26.3A beta update: security testing changes, installation guide, known bugs, and what it means for Apple’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback